Abstract:Our study indicated that the 14‐gene‐related prognostic signature gene could serve as a novel biomarker for predicting breast cancer patients' prognosis. We found that immunotherapy might play a vital role in therapeutic schedule based on the level and difference of immune‐related cells and pathways in different risk groups. Background Breast cancer (BC), a malignant tumor, is a significant cause of death and disability among women globally. Recent research indicates that copy number variation plays a crucial role in tumor development. In this study, we employed the Single‐Cell Variational Aneuploidy Analysis (SCEVAN) algorithm to differentiate between malignant and non‐malignant cells, aiming to identify genetic signatures with prognostic relevance for predicting patient survival. Methods We analyzed gene expression profiles and associated clinical data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases. Using the SCEVAN algorithm, we distinguished malignant from non‐malignant cells and investigated cellular interactions within the tumor microenvironment (TME). We categorized TCGA samples based on differentially expressed genes (DEGs) between these cell types. Subsequent Kyoto Encyclopedia of Genes and Genomes pathway analysis was conducted. Additionally, we developed polygenic models for the DEGs using least absolute shrinkage and selection operator‐penalized Cox regression analysis. To assess the prognostic accuracy of these characteristics, we generated Kaplan–Meier and receiver operating characteristic curves from training and validation datasets. We also monitored the expression variations of prognostic genes across the pseudotime of malignant cells. Patients were divided into high‐risk and low‐risk groups based on median risk scores to compare their TME and identify potential therapeutic agents. Lastly, polymerase chain reaction was used to validate seven pivotal genes. Results The SCEVAN algorithm identified distinct malignant and non‐malignant cells in GSE180286. Cellchat analysis revealed significantly increased cellular communication, particularly between fibroblasts, endothelial cells and malignant cells. The DEGs were predominantly involved in immune‐related pathways. TCGA samples were classified into clusters A and B based on these genes. Cluster A, enriched in immune pathways, was associated with poorer prognosis, whereas cluster B, predominantly involved in circadian rhythm pathways, showed better outcomes. We constructed a 14‐gene prognostic signature, validated in a 1:1 internal TCGA cohort and external GEO datasets (GSE42568 and GSE146558). Kaplan–Meier analysis confirmed the prognostic signature's accuracy (p

Four‐gene signature based on machine learning filtration could predict prognosis of patients with breast cancer

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

A 41-Gene Signature Derived from Breast Cancer Stem Cells As a Predictor of Survival

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Predicting gene signature in breast cancer patients with multiple machine learning models

Development of a novel prognostic signature based on single‐cell combined bulk RNA analysis in breast cancer

Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients

Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis

A Prognostic 4-Gene Expression Signature for Patients with HER2-negative Breast Cancer Receiving Taxane and Anthracycline-Based Chemotherapy

Identification of a Four-Gene Signature Associated with the Prognosis Prediction of Lung Adenocarcinoma Based on Integrated Bioinformatics Analysis

A Four-Long Non-Coding RNA Signature in Predicting Breast Cancer Survival

A Novel Glycolysis-Related Four-mRNA Signature for Predicting the Survival of Patients With Breast Cancer

A new 4-gene-based prognostic model accurately predicts breast cancer prognosis and immunotherapy response by integrating WGCNA and bioinformatics analysis

A four-gene prognostic signature for predicting the overall survival of patients with lung adenocarcinoma

Tumor Microenvironment-Related Multigene Prognostic Prediction Model for Breast Cancer

A Novel Four-Gene Signature as a Potential Prognostic Biomarker for Hepatocellular Carcinoma

A Metabolic Gene Signature to Predict Breast Cancer Prognosis

A Gene Signature for Breast Cancer Prognosis Using Support Vector Machine

Identification of a four-gene panel predicting overall survival for lung adenocarcinoma

A Signature Constructed with Mitophagy-Related Genes to Predict the Prognosis and Therapy Response for Breast Cancer.

Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China